18+

 

Number №3, 2021 - page 136-140

Clinical use of cytomedin in patients with prostate diseases DOI: 10.29188/2222-8543-2021-14-3-136-140

For citation: Ergakov D.V., Martov A.G., Asliev K.A. Clinical use of cytomedin in patients with prostate diseases. Experimental and Clinical Urology 2021;14(3):136-140; https://doi.org/10.29188/2222-8543-2021-14-3-136-140
Ergakov D.V., Martov A.G., Asliev K.A.
Information about authors:
  • Ergakov D.V. – PhD, Associate Professor of the Department of Urology and Androlog of Federal Medical and Biological Center named after A.I. Burnazyana FMBA RF, urologist of the Urology Department of State Budgetary Health city hospital named after D.D. Pletnev; Moscow, Russia; https://orcid.org/0000-0003-1682-7208
  • Martov A.G. – Dr.Sc., Professor, Chief Department of urology and andrology FSBI, Federal Medical Biophysical Center named after A.I. Burnazyan FMBA; Chief Department of urology City Clinical Hospital named after D.D. Pletnev; Moscow, Russia; https://orcid.org/0000-0001-6324-6110
  • Asliev K.A. – Doctor of the 2nd urological department of the City Clinical hospital named after D.D. Pletnev; Moscow, Russia
661

Introduction. The use of extracts of the prostate of animals is one of the main directions in the treatment of patients with diseases of the prostate. Most studies describe the experience of using these drugs in a small number of patients for a limited time period. The aim of this work was to summarize the long-term experience of using drugs of the cytomedin group in the treatment of a large number of patients with chronic prostatitis (CP) and benign prostatic hyperplasia (BPH).

Materials and methods. Cytomedins were used in 487 patients with CP / BPH from January 2015 to December 2018. Indications: rehabilitation of patients after pancreatic biopsy (63 patients, 13%), cystoscopy and other endoscopic surgical interventions (189 patients, 39%), as well as conservative therapy of chronic inflammation associated with BPH (235 patients, 48%). If an infectious-inflammatory process was suspected, the following scheme was used: Vitaprost® Plus 1 candle 1 time per day for 20 days, in the presence of irritative complaints, Vitaprost® Forte was used 1 candle 1 time per day for 20 days, in other cases Vitaprost® was prescribed 1 candle 1 time per day for 20 days. The second component of the complex treatment was the use of the Vitaprost® tablet form for 20 days, 1 ton 2 times a day. Before and after the appointment of therapy, the quality of life was monitored according to the data of the visual analogue scale (VAS), ultrasound examination of the pancreas (ultrasound) and laboratory parameters. The results of therapy were assessed as successful with an improvement in the quality of life, a decrease in the level of leukocytes, and a decrease in the volume of the pancreas by more than 10% from the initial level.

Results. The total efficacy of cytomedin therapy was 39%. The greatest effectiveness of therapy was with the initial VAS less than 60 points out of 100; with more severe pain syndrome, the effectiveness was statistically significantly reduced to 32%. The initial detection of an inflammatory component with an increase in the level of leukocytes in laboratory tests statistically significantly increased the effectiveness of therapy 48 versus 24%. Cytomedin therapy was equally effective regardless of the prostate volume (36% versus 42% versus 38%, p> 0.05). A survey was conducted in 102 patients after Vitaprost® Forte/Vitaprost® therapy, the results of which revealed a decrease in the I-PSS score from 18 ± 6.4 points to 12 ± 4 points (p> 0.05), in the group with combination therapy with alpha adrenergic blockers – 8 ± 3.2 points, p 0.05) versus 18 ± 3.4 points before treatment.

Conclusions. the following prognostic criteria for the effectiveness of cytomedin therapy were determined: the level of the visual analogue scale is less than 60 out of 100 and the presence of a confirmed inflammatory component according to laboratory tests.

AttachmentSize
Download223.59 KB
cytomedins; Vitaprost®; chronic prostatitis; lower urinary tract symptoms; LUTS; benign prostatic hyperplasia; BPH

Readera - Социальная платформа публикаций

Crossref makes research outputs easy to find, cite, link, and assess